<DOC>
	<DOCNO>NCT00509600</DOCNO>
	<brief_summary>Primary Objectives : 1.1 Estimate rate response define acute toxicity etanercept use up-front phase II window newly diagnose relapse JMML . 1.2 Determine response Tumor Necrosis Factor ( TNF ) blockade correlate genetic basis Juvenile Myelomonocytic Leukemia ( JMML ) [ mutation NF1 , Ras , SHP2 ] level TNFa . 1.3 Determine TNF blockade etanercept result inhibition free level TNFa cytokine ELISA bioassay improves blood count . 1.4 Estimate two year event free survival overall survival JMML patient follow etanercept allogeneic hematopoietic stem cell transplantation .</brief_summary>
	<brief_title>Etanercept ( Enbrel ) Juvenile Myelomonocytic Leukemia</brief_title>
	<detailed_description>Etanercept block hormone call Tumor Necrosis Factor ( TNF ) , show play role help growth leukemic cell JMML . Before participant start treatment study , call `` screening test '' . These test help doctor decide patient eligible take part study . You complete medical history physical exam . About two tablespoon blood urine collected routine test well test liver kidney function . You bone marrow biopsy perform monitor disease activity . To collect bone marrow biopsy , area hip chest bone numb anesthetic small amount bone marrow bone withdrawn large needle . You cell inside mouth test genetic change swab side cheek . If find eligible , etanercept give injection skin week 90 day . During study , weekly follow-up test include physical exam lab test . About 2 tablespoon blood collect time . Urine also collect test least every 3 week study . If disease get bad intolerable side effect occur , take study alternative treatment option discuss . This investigational study . The FDA approve etanercept use adult child rheumatoid arthritis juvenile rheumatoid arthritis . Its use study experimental . A total 30 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>1 . All child great 6 month age less 18 year age newlydiagnosed previously untreated previously diagnose JMML , reoccurred treatment chemotherapy , stem cell transplantation , and/or cisretinoic acid . 2 . A diagnosis JMML confirm follow criterion JMML meet : ) ALL following : Absence ( 9 ; 22 ) BCRABL PCR FISH ; Absolute monocyte count &gt; 1000 ( 1 X 109/µL ) ; &lt; 20 % bone marrow blast ; b ) At least 2 follow : Elevated Hb F hemoglobin ; Myeloid precursor peripheral blood ; WBC &gt; 10,000 ( 10 X 109/µL ) ; GMCSF hypersensitivity methylcellulose culture bone marrow progenitor cell . 3 . Adequate hepatic function ( bilirubin equal less 2.0 mg/dl ; ALT equal less 3x normal ) 4 . Adequate renal function ( serum creatinine equal le 2 x normal ) 5 . Performance Status : Have Karnofsky score &gt; 50 . 6 . Written , inform consent accord institution guideline . 1 . Pregnant lactating . 2 . Receiving chemotherapy . Patients must chemotherapy least 2 week must recover acute toxicity previous therapy prior enrollment . 3 . Febrile neutropenia study entry .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Juvenile Myelomonocytic Leukemia</keyword>
	<keyword>JMML</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Etanercept</keyword>
	<keyword>Enbrel</keyword>
</DOC>